DiaMedica Therapeutics Inc. Common Stock/$DMAC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Ticker
$DMAC
Sector
Primary listing
Employees
28
Headquarters
Website
DMAC Metrics
BasicAdvanced
$355M
-
-$0.69
1.24
-
Price and volume
Market cap
$355M
Beta
1.24
52-week high
$7.49
52-week low
$3.19
Average daily volume
430K
Financial strength
Current ratio
7.551
Quick ratio
7.337
Long term debt to equity
0.677
Total debt to equity
1.075
Profitability
EBITDA (TTM)
-31.418
Effective tax rate (TTM)
-0.09%
Management effectiveness
Return on assets (TTM)
-44.55%
Return on equity (TTM)
-73.41%
Valuation
Price to book
10.89
Price to tangible book (TTM)
10.89
Price to free cash flow (TTM)
-11.461
Free cash flow yield (TTM)
-8.73%
Free cash flow per share (TTM)
-0.599
Growth
Earnings per share change (TTM)
31.80%
3-year earnings per share growth (CAGR)
7.79%
10-year earnings per share growth (CAGR)
0.01%
What the Analysts think about DMAC
Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
Bulls say / Bears say
Interim Phase 2 preeclampsia data showed highly statistically significant reductions in systolic and diastolic blood pressure with no detectable transfer of DM199 to the placenta, highlighting its potential as a first-in-class therapy in an area with no approved treatments (Business Wire).
The Phase 2 PACTR202404895013782 preeclampsia trial is close to identifying the most clinically relevant therapeutic dose in Part 1a, with topline safety and efficacy results expected soon, creating a near-term catalyst (Business Wire).
DiaMedica has reported a cash runway into Q3 2026, indicating sufficient funding to complete its ongoing AIS and preeclampsia clinical programs without near-term financing pressure (Business Wire).
Enrollment in the ReMEDy2 Phase 2/3 acute ischemic stroke trial has been slow, and multiple protocol amendments have pushed the planned interim sample size re-estimation for the first 200 participants into the first half of 2026. This will delay any pivotal efficacy results and regulatory discussions for the stroke program (Business Wire).
The positive interim preeclampsia Part 1a results come from small combined cohorts of 6 to 9 participants in an investigator-sponsored study. Confirmatory data from the larger Part 1b expansion will be required before any clinical benefit and safety can be established at scale (Business Wire).
Cash, cash equivalents, and short-term investments fell from $44.1 million at year-end 2024 to $37.3 million on March 31, 2025, implying a quarterly cash burn of about $6.8 million. This will require additional financing by Q3 2026 and could result in shareholder dilution (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2025.
DMAC Financial Performance
Revenues and expenses
DMAC Earnings Performance
Company profitability
DMAC News
AllArticlesVideos
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
Business Wire2 weeks ago
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
Business Wire2 weeks ago
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $355M as of September 18, 2025.
What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?
The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of September 18, 2025.
Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?
No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of September 18, 2025.
When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?
DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.
What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.